A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Palmoplantar Pustulosis

In brief

A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)

Key facts

Study ID

NCT03633396

Run by

Vanda Pharmaceuticals

People needed

59

Starts

2019-05-20

Expected to finish

2021-04-23

Last updated by the study team

2025-09-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically confirmed diagnosis of PPP
• Disease duration of at least 6 months prior to screening
• Present with active pustules on palms or/and soles at screening

You may not qualify if…

• Any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy
• History of recurrent or active/serious infection
• Ongoing use of psoriasis prohibited medication
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Investigational Site — Birmingham, Alabama, United States
• Investigational Site — Phoenix, Arizona, United States
• Investigational Site — Encino, California, United States
• Investigational Site — Santa Monica, California, United States
• Investigational Site — Fort Lauderdale, Florida, United States
• Investigational Site — Miami, Florida, United States
• Investigational Site — Pembroke Pines, Florida, United States
• Investigational Site — Tampa, Florida, United States
• Investigational Site — Indianapolis, Indiana, United States
• Investigational Site — Plainfield, Indiana, United States
• Investigational Site — Overland Park, Kansas, United States
• Investigational Site — Ann Arbor, Michigan, United States
• Investigational Site — St Louis, Missouri, United States
• Investigational Site — St Louis, Missouri, United States
• Investigational Site — Wilmington, North Carolina, United States
• Investigational Site — Columbus, Ohio, United States
• Investigational Site — Norman, Oklahoma, United States
• Investigational Site — Portland, Oregon, United States
• Investigational Site — Dallas, Texas, United States
• Investigational Site — Surrey, British Columbia, Canada
• Investigational Site — Greater Sudbury, Ontario, Canada
• Investigational Site — Markham, Ontario, Canada
• Investigational Site — Drummondville, Quebec, Canada
• Investigational Site — Montreal, Quebec, Canada
• Investigational Site — Bad Bentheim, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.